Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of “Buy” by Brokerages

Apogee Therapeutics, Inc. (NASDAQ:APGE) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $71.83.

APGE has been the subject of a number of research reports. Guggenheim boosted their price target on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Jefferies Financial Group raised their price target on Apogee Therapeutics from $37.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Stifel Nicolaus upped their price objective on Apogee Therapeutics from $46.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Finally, Wedbush restated an “outperform” rating and issued a $87.00 target price (up previously from $40.00) on shares of Apogee Therapeutics in a research report on Tuesday, March 5th.

Apogee Therapeutics Trading Down 1.8 %

Shares of APGE stock opened at $51.26 on Friday. Apogee Therapeutics has a 52-week low of $14.19 and a 52-week high of $72.29. The business’s fifty day moving average is $57.14 and its 200 day moving average is $37.12.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. As a group, equities research analysts predict that Apogee Therapeutics will post -2.67 earnings per share for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank bought a new stake in Apogee Therapeutics in the third quarter valued at approximately $52,000. Strs Ohio bought a new stake in Apogee Therapeutics during the 3rd quarter valued at $87,000. New York State Common Retirement Fund purchased a new stake in Apogee Therapeutics during the 3rd quarter valued at $90,000. SG Americas Securities LLC bought a new stake in Apogee Therapeutics in the 3rd quarter worth $105,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Apogee Therapeutics in the first quarter valued at about $339,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.